Luxbright AB (SE:LXB)
:LXB
Want to see SE:LXB full AI Analyst Report?
Top Page
Luxbright AB
(LXB)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.14
▼(-70.00% Downside)
Action:ReiteratedDate:04/23/26
The score is primarily held down by weak financial performance—ongoing losses, unstable margins, and sustained cash burn—despite a low-debt balance sheet. Technicals further pressure the score with a clear downtrend and very weak momentum indicators. Valuation provides limited support because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
Low leverage / strong balance sheet resilience
Minimal reported debt and low leverage give Luxbright durable financial flexibility, reducing bankruptcy risk and extending runway versus highly leveraged peers. This structural strength helps the company weather continued R&D and commercialization costs while seeking profitability or additional funding.
Negative Factors
Persistent large net losses
Ongoing large net losses indicate the company has not yet converted top-line growth into profitability. Persistently negative earnings erode equity value, limit internal funding for R&D and commercial expansion, and create long-term reliance on external capital unless margins and operating efficiency improve materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet resilience
Minimal reported debt and low leverage give Luxbright durable financial flexibility, reducing bankruptcy risk and extending runway versus highly leveraged peers. This structural strength helps the company weather continued R&D and commercialization costs while seeking profitability or additional funding.
Read all positive factors
Luxbright AB (LXB) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr39.04M
Dividend YieldN/A
Average Volume (3M)49.93K
Price to Earnings (P/E)―
Beta (1Y)-0.56
Revenue Growth27.31%
EPS Growth6.31%
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.07
Shares Outstanding260,296,020
10 Day Avg. Volume14,295
30 Day Avg. Volume49,930
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.09
Price to Sales (P/S)4.94
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr35.75M
Luxbright AB Business Overview & Revenue Model
Company Description
Luxbright AB (publ), a technology company, develops and commercializes X-ray tubes, generators, and X-ray systems to system suppliers. The company was incorporated in 2012 and is headquartered in Gothenburg, Sweden....
How the Company Makes Money
Publicly available, company-specific detail on Luxbright AB’s current revenue model, revenue streams, customer contracts, pricing, or material partnerships is not available in the information provided, so a factual detailed explanation cannot be g...
Luxbright AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.41M | 9.02M | 854.70K | 811.70K | 729.00K |
| Gross Profit | -21.37M | 8.88M | -2.80M | 189.12K | 1.98M |
| EBITDA | -16.76M | -15.72M | -23.87M | -20.47M | -17.63M |
| Net Income | -19.46M | -17.72M | -25.38M | -21.13M | -18.10M |
Balance Sheet | |||||
| Total Assets | 39.38M | 42.66M | 40.69M | 31.19M | 23.99M |
| Cash, Cash Equivalents and Short-Term Investments | 5.29M | 12.36M | 14.04M | 7.60M | 7.51M |
| Total Debt | 0.00 | 254.19K | 206.02K | 588.34K | 1.10M |
| Total Liabilities | 12.49M | 8.46M | 7.00M | 3.33M | 3.36M |
| Stockholders Equity | 26.89M | 34.20M | 33.69M | 27.86M | 20.63M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -16.52M | -20.39M | -20.64M | -17.14M |
| Operating Cash Flow | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Investing Cash Flow | -3.65M | -3.44M | -3.99M | -7.15M | -4.15M |
| Financing Cash Flow | 16.46M | 18.28M | 30.82M | 27.88M | -708.00K |
Luxbright AB Technical Analysis
Negative
0.48
Price Trends
0.33
Negative
0.41
Negative
0.54
Negative
Market Momentum
-0.07
Positive
17.49
Positive
7.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.33, and below the 200-day MA of 0.54, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 17.49 is Positive, neither overbought nor oversold. The STOCH value of 7.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.
Luxbright AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | kr107.31M | 35.29 | ― | ― | -12.51% | -59.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr338.80M | -1.43 | -253.54% | ― | 36.21% | 11.93% | |
44 Neutral | kr55.87M | -8.36 | ― | ― | -9.56% | 51.30% | |
43 Neutral | kr107.52M | -4.28 | -61.62% | ― | -6.90% | 45.52% | |
43 Neutral | kr39.20M | -1.14 | -50.21% | ― | ― | -104.27% | |
42 Neutral | kr39.04M | -2.89 | -60.56% | ― | 27.31% | 6.31% |
* Healthcare Sector Average
SE:LXB
Luxbright AB
0.15
-0.61
-80.18%
SE:SCIB
SciBase Holding AB
0.41
0.09
27.81%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.45
0.50
16.95%
SE:SPEC
SpectraCure AB
0.07
-0.26
-79.20%
SE:SDOS
ScandiDos AB
0.98
-0.30
-23.44%
SE:ARCOMA
Arcoma AB
7.50
-1.40
-15.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.